NovoCure (NVCR) CEO gets major equity grants and sells shares for taxes

Rhea-AI Filing Summary

NovoCure Ltd Chief Executive Officer Leonard Frank X reported a mix of equity awards and a small share sale. He received a grant of 150,000 ordinary shares in the form of restricted share units that vest in three equal parts on the first, second and third anniversaries of the grant date, subject to continued employment. He also received stock options for 216,388 ordinary shares that vest in four equal parts on the first through fourth anniversaries of the grant date, also subject to continued employment. To cover tax withholding obligations from restricted stock unit vesting, he sold 5,607 ordinary shares in a mandated “sell to cover” transaction at a weighted average price of $13.3054 per share, executed in multiple trades between $13.21 and $13.445. Following these transactions, he directly holds 493,793 ordinary shares and 216,388 stock options.

Insider Trade Summary

Net Seller: 5,607 shares ($74,603)

Net Sell 3 txns

Insider Leonard Frank X

Role Chief Executive Officer

Sold 5,607 shs ($75K)

Type	Security	Shares	Price	Value
Sale	Ordinary Shares	5,607	$13.3054	$75K
Grant/Award	Stock Option (Right to Buy)	216,388	$0.00	--
Grant/Award	Ordinary Shares	150,000	$0.00	--

Holdings After Transaction: Ordinary Shares — 493,793 shares (Direct); Stock Option (Right to Buy) — 216,388 shares (Direct)

Footnotes (1)

1. Represents restricted share units that are scheduled to vest in equal parts on the first, second and third anniversary of the grant date, subject to the reporting person's continued employment through such dates. Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. This transaction was executed in multiple trades at prices ranging from $13.21 USD to $13.445 USD; the price reported above reflects the weighted average sale price. Options to buy ordinary shares that are scheduled to vest in equal parts on the first, second, third and fourth anniversary of the grant date, subject to the reporting person's continued employment through such date.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Leonard Frank X

(Last) (First) (Middle)

C/O NOVOCURE INC.

1550 LIBERTY RIDGE DRIVE, SUITE 115

(Street)

WAYNE PA 19087

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
NovoCure Ltd [ NVCR ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

3. Date of Earliest Transaction (Month/Day/Year)
03/03/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Ordinary Shares(1)	03/03/2026		A		150,000	A	$0.00	499,400	D
Ordinary Shares	03/04/2026		S		5,607(2)	D	$13.3054(3)	493,793	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$13.3	03/03/2026		A		216,388		(4)	03/03/2036	Ordinary Shares	216,388	$0.00	216,388	D

Explanation of Responses:

1. Represents restricted share units that are scheduled to vest in equal parts on the first, second and third anniversary of the grant date, subject to the reporting person's continued employment through such dates.

2. Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.

3. This transaction was executed in multiple trades at prices ranging from $13.21 USD to $13.445 USD; the price reported above reflects the weighted average sale price.

4. Options to buy ordinary shares that are scheduled to vest in equal parts on the first, second, third and fourth anniversary of the grant date, subject to the reporting person's continued employment through such date.

Remarks:

	Steven Robbins, as attorney in fact for Leonard, Frank X.	03/05/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did NovoCure (NVCR) CEO Leonard Frank X report in this Form 4?

NovoCure CEO Leonard Frank X reported new equity awards and a small tax-related share sale. He received 150,000 restricted share units, 216,388 stock options, and sold 5,607 ordinary shares in a mandated transaction to cover tax withholding obligations linked to vesting.

How many restricted share units did NovoCure (NVCR) grant to its CEO and how do they vest?

NovoCure granted its CEO 150,000 restricted share units that convert into ordinary shares over time. These units are scheduled to vest in three equal installments on the first, second and third anniversaries of the grant date, subject to his continued employment through each vesting date.

What stock options did NovoCure (NVCR) CEO receive in the latest filing?

The CEO received stock options for 216,388 ordinary shares at a grant price of $0.0000. These options vest in four equal parts on the first, second, third and fourth anniversaries of the grant date, provided he remains employed through each respective vesting date.

Why did the NovoCure (NVCR) CEO sell 5,607 ordinary shares?

He sold 5,607 ordinary shares solely to cover tax withholding obligations from restricted stock unit vesting. The sale was mandated by NovoCure’s equity award agreement as a “sell to cover” transaction and did not represent a discretionary trade initiated for portfolio or cash-raising reasons.

At what price were the NovoCure (NVCR) CEO’s tax-related shares sold?

The 5,607 ordinary shares were sold at a weighted average price of $13.3054 per share. The transaction occurred in multiple trades executed at prices ranging from $13.21 to $13.445 per share, reflecting normal market execution within that stated price range.

How many NovoCure (NVCR) shares does the CEO hold after these transactions?

After these transactions, the CEO directly holds 493,793 ordinary shares of NovoCure. In addition, he holds stock options covering 216,388 ordinary shares, which are scheduled to vest in four equal annual installments following the grant date, subject to continued employment conditions.